All In Biotech

Drug Trial Radar · NCT04429542

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

473

Planned (sponsor's estimate)

Start

Jun 1, 2020

Primary completion

Oct 31, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
Bicara TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

Conditions

  • Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Anal Canal
  • Colorectal Cancer
  • Squamous Cell Carcinoma of the Lung
  • EGFR Amplification
  • Epithelial Ovarian Cancer
  • Pancreas Cancer
  • Cutaneous Squamous Cell Carcinoma
  • Head and Neck Neoplasms
  • Carcinoma, Squamous Cell
  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • BCA101Drug

    EGFR/TGFβ fusion monoclonal antibody

  • PembrolizumabDrug

    anti-PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEsTime frame: 24 months
  2. Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEsTime frame: 24 months
  3. Incidence of Dose Limiting Toxicities (DLTs)Time frame: 21 days

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Moores Cancer Center UC San Diego Health

    La Jolla, California · Recruiting

  • Keck School of Medicine of USC

    Los Angeles, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • H. Lee Moffitt Cancer Center and Research Institute, Inc

    Tampa, Florida · Recruiting

  • Dana Farber/Partners Cancer Care Inc

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • Columbia University Herbert Irving Comprehensive Cancer Center

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina, Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.